Note: This document contains side effect information about mirvetuximab soravtansine. Some dosage forms listed on this page may not apply to the brand name Elahere.

Applies to mirvetuximab soravtansine: intravenous solution.

Serious side effects of Elahere

Along with its needed effects, mirvetuximab soravtansine (the active ingredient contained in Elahere) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mirvetuximab soravtansine:

More common

• Black, tarry stools
• blindness
• blurred vision
• burning, numbness, tingling, or painful sensations
• change in vision
• chills
• cough
• decreased vision
• difficulty seeing at night
• double vision
• dry eye
• eye redness, irritation, or pain
• fever
• increased sensitivity of the eyes to sunlight
• lower back or side pain
• nausea
• painful, irritation of the clear front part of the eye
• painful or difficult urination
• pale skin
• seeing double
• severe constipation
• sore throat
• stomach pain
• trouble breathing
• ulcers, sores, or white spots in the mouth
• unsteadiness or awkwardness
• unusual bleeding or bruising
• unusual tiredness or weakness
• vomiting
• watering of the eyes
• weakness in the arms, hands, legs, or feet

Less common

• Bleeding gums
• blood in the urine or stools
• chest pain
• cough or hoarseness
• general feeling of discomfort or illness
• pinpoint red spots on the skin
• stomach bloating
• thickening of bronchial secretions

Other side effects of Elahere

Some side effects of mirvetuximab soravtansine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Decreased appetite
• diarrhea
• muscle or joint pain

For Healthcare Professionals

Applies to mirvetuximab soravtansine: intravenous solution.

Gastrointestinal

Very common (10% or more): Abdominal distension (11%), abdominal pain (36%), constipation (30%), diarrhea (31%), nausea (40%), vomiting (19%)^[Ref]

General

-The most common adverse reactions with a frequency of 20% or more, including laboratory abnormalities, were vision impairment, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin.

-The most common side effects resulting in discontinuation were intestinal obstruction (2%) and thrombocytopenia (2%).

-Serious adverse reactions were reported in 31% of patients, of which the most common were intestinal obstruction, ascites, infection, and pleural effusion.^[Ref]

Hematologic

Common (1% to 10%): Thrombocytopenia^[Ref]

Hypersensitivity

Common (1% to 10%): Infusion related reactions/hypersensitivity^[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (17%), myalgia (10%)^[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (33%)^[Ref]

Ocular

Very common (10% or more): Cataract (18%), dry eye (27%), eye pain (10%), keratopathy (37%), photophobia (17%), vision impairment (50%)

Common (1% to 10%): Uveitis^[Ref]

Other

Very common (10% or more): Fatigue (49%)^[Ref]

Respiratory

Very common (10% or more): Dyspnea (12%)

Common (1% to 10%): Pneumonitis^[Ref]

Metabolic

Very common (10% or more): Decreased appetite (18%)^[Ref]